Skip to content

Clinical trials

Active, not recruiting Phase 2 Leukemia, Myeloid, Acute trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Myeloid, Acute Phase: Phase 2 Status: Active, not recruiting Clear all

70 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20081
20111
20121
20142
20151
20164
20175
20184
201911
20207
202110
20227
20238
20246
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Active, not recruiting70

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)9
M.D. Anderson Cancer Center6
City of Hope Medical Center5
St. Jude Children's Research Hospital4
French Innovative Leukemia Organisation3
The First Affiliated Hospital of Soochow University3
Bristol-Myers Squibb2
Center for International Blood and Marrow Transplant Research2
Groupe Francophone des Myelodysplasies2
Massachusetts General Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Myeloid, Acute70
Myelodysplastic Syndromes21
Precursor Cell Lymphoblastic Leukemia-Lymphoma13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive6
Leukemia, Myelomonocytic, Chronic6
Hodgkin Disease5
Leukemia5
Lymphoma, Non-Hodgkin5
Myeloproliferative Disorders5
Primary Myelofibrosis5

Trials

Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.